MRKMerck Sharp & Dohme LLCFinished
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Renal Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 160 (final count)
- Started
- Feb 23, 2021
- Main results expected
- Jan 27, 2025
- Fully finished
- Oct 21, 2025
- Results posted
- Dec 3, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to approximately 47 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04704219 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC